Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - GEN LB - 1. AU - Cancer Research UK TI - Myeloma Incidence Statistics CY - London PB - Cancer Research UK PY - 2014 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma M1 - 30 November 2017 ER - TY - JOUR LB - 2. AU - Kumar, SK AU - Rajkumar, SV AU - Dispenzieri, A AU - Lacy, MQ AU - Hayman, SR AU - Buadi, FK TI - Improved survival in multiple myeloma and the impact of novel therapies J2 - Blood PY - 2008 VL - 111 SP - 2516 EP - 2520 UR - https://doi.org/10.1182/blood-2007-10-116129 ER - TY - JOUR LB - 3. AU - Bird, J AU - Behrens, J AU - Westin, J AU - Turesson, I AU - Drayson, M AU - Beetham, R TI - UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) J2 - Br J Haematol PY - 2009 VL - 147 SP - 22 EP - 42 UR - https://doi.org/10.1111/j.1365-2141.2009.07807.x ER - TY - JOUR LB - 4. AU - Landgren, O AU - Kyle, RA AU - Pfeiffer, RM AU - Katzmann, JA AU - Caporaso, NE AU - Hayes, RB TI - Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study J2 - Blood PY - 2009 VL - 113 SP - 5412 EP - 5417 UR - https://doi.org/10.1182/blood-2008-12-194241 ER - TY - JOUR LB - 5. AU - Augustson, BM AU - Begum, G AU - Dunn, JA AU - Barth, NJ AU - Davies, F AU - Morgan, G TI - Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party J2 - J Clin Oncol PY - 2005 VL - 23 SP - 9219 EP - 9226 UR - https://doi.org/10.1200/JCO.2005.03.2086 ER - TY - JOUR LB - 6. AU - Perri, RT AU - Hebbel, RP AU - Oken, MM TI - Influence of treatment and response status on infection risk in multiple myeloma J2 - Am J Med PY - 1981 VL - 71 SP - 935 EP - 940 UR - https://doi.org/10.1016/0002-9343(81)90303-X ER - TY - JOUR LB - 7. AU - Lenhoff, S AU - Hjorth, M AU - Holmberg, E AU - Turesson, I AU - Westin, J AU - Nielsen, JL TI - Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group J2 - Blood PY - 2000 VL - 95 SP - 7 EP - 11 ER - TY - JOUR LB - 8. AU - Blade, J AU - San Miguel, JF AU - Fontanillas, M AU - Esteve, J AU - Maldonado, J AU - Alcala, A TI - Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients J2 - Hematol J PY - 2001 VL - 2 SP - 272 EP - 278 UR - https://doi.org/10.1038/sj.thj.6200115 ER - TY - JOUR LB - 9. AU - Morgan, GJ AU - Davies, FE AU - Gregory, WM AU - Bell, SE AU - Szubert, AJ AU - Navarro Coy, N TI - Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results J2 - Haematologica PY - 2012 VL - 97 SP - 442 EP - 450 UR - https://doi.org/10.3324/haematol.2011.043372 ER - TY - JOUR LB - 10. AU - Cohen, HJ AU - Rundles, RW TI - Managing the complications of plasma cell myeloma J2 - Arch Intern Med PY - 1975 VL - 135 SP - 177 EP - 184 UR - https://doi.org/10.1001/archinte.1975.00330010179023 ER - TY - JOUR LB - 11. AU - Savage, DG AU - Lindenbaum, J AU - Garrett, TJ TI - Biphasic pattern of bacterial infection in multiple myeloma J2 - Ann Intern Med PY - 1982 VL - 96 SP - 47 EP - 50 UR - https://doi.org/10.7326/0003-4819-96-1-47 ER - TY - JOUR LB - 12. AU - Espersen, F AU - Birgens, HS AU - Hertz, JB AU - Drivsholm, A TI - Current patterns of bacterial infection in myelomatosis J2 - Scand J Infect Dis PY - 1984 VL - 16 SP - 169 EP - 173 UR - https://doi.org/10.3109/00365548409087137 ER - TY - JOUR LB - 13. AU - Jacobson, DR AU - Zolla-Pazner, S TI - Immunosuppression and infection in multiple myeloma J2 - Semin Oncol PY - 1986 VL - 13 SP - 282 EP - 290 ER - TY - JOUR LB - 14. AU - Doughney, KB AU - Williams, DM AU - Penn, RL TI - Multiple myeloma: infectious complications J2 - South Med J PY - 1988 VL - 81 SP - 855 EP - 858 UR - https://doi.org/10.1097/00007611-198807000-00012 ER - TY - JOUR LB - 15. AU - Rayner, HC AU - Haynes, AP AU - Thompson, JR AU - Russell, N AU - Fletcher, J TI - Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988 J2 - Q J Med PY - 1991 VL - 79 SP - 517 EP - 525 ER - TY - JOUR LB - 16. AU - Heaney, JLJ AU - Campbell, JP AU - Iqbal, G AU - Caims, D AU - Richter, A AU - Child, JA TI - Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials [published online ahead of print 20 June 2018] J2 - Leukemia PY - 2018 ER - TY - JOUR LB - 17. AU - Pratt, G AU - Goodyear, O AU - Moss, P TI - Immunodeficiency and immunotherapy in multiple myeloma J2 - Br J Haematol PY - 2007 VL - 138 SP - 563 EP - 579 UR - https://doi.org/10.1111/j.1365-2141.2007.06705.x ER - TY - JOUR LB - 18. AU - Oken, MM AU - Pomeroy, C AU - Weisdorf, D AU - Bennett, JM TI - Prophylactic antibiotics for the prevention of early infection in multiple myeloma J2 - Am J Med PY - 1996 VL - 100 SP - 624 EP - 628 UR - https://doi.org/10.1016/S0002-9343(95)00043-7 ER - TY - JOUR LB - 19. AU - Vesole, DH AU - Oken, MM AU - Heckler, C AU - Greipp, PR AU - Katz, MS AU - Jacobus, S TI - Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study J2 - Leukemia PY - 2012 VL - 26 SP - 2517 EP - 2520 UR - https://doi.org/10.1038/leu.2012.124 ER - TY - JOUR LB - 20. AU - Offidani, M AU - Corvatta, L AU - Polloni, C AU - Gentili, S AU - Mele, A AU - Rizzi, R TI - Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma J2 - Ann Hematol PY - 2011 VL - 90 SP - 1449 EP - 1456 UR - https://doi.org/10.1007/s00277-011-1217-0 ER - TY - JOUR LB - 21. AU - Vidal, L AU - Gafter-Gvili, A AU - Leibovici, L AU - Dreyling, M AU - Ghielmini, M AU - Hsu Schmitz, SF TI - Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials J2 - J Natl Cancer Inst PY - 2009 VL - 101 SP - 248 EP - 255 UR - https://doi.org/10.1093/jnci/djn478 ER - TY - JOUR LB - 22. AU - Bucaneve, G AU - Micozzi, A AU - Menichetti, F AU - Martino, P AU - Dionisi, MS AU - Martinelli, G TI - Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia J2 - N Engl J Med PY - 2005 VL - 353 SP - 977 EP - 987 UR - https://doi.org/10.1056/NEJMoa044097 ER - TY - JOUR LB - 23. AU - Cullen, M AU - Steven, N AU - Billingham, L AU - Gaunt, C AU - Hastings, M AU - Simmonds, P TI - Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas J2 - N Engl J Med PY - 2005 VL - 353 SP - 988 EP - 998 UR - https://doi.org/10.1056/NEJMoa050078 ER - TY - JOUR LB - 24. AU - Gafter-Gvili, A AU - Fraser, A AU - Paul, M AU - Vidal, L AU - Lawrie, TA AU - van de Wetering, MD TI - Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy J2 - Cochrane Database Syst Rev PY - 2012 VL - 1 UR - https://doi.org/10.1002/14651858.CD004386.pub3 ER - TY - JOUR LB - 25. AU - Leibovici, L AU - Paul, M AU - Cullen, M AU - Bucaneve, G AU - Gafter-Gvili, A AU - Fraser, A AU - Kern, WV TI - Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions J2 - Cancer PY - 2006 VL - 107 SP - 1743 EP - 1751 UR - https://doi.org/10.1002/cncr.22205 ER - TY - JOUR LB - 26. AU - Meunier, F AU - Lukan, C TI - The first European conference on infections in leukaemia – ECIL1: a current perspective J2 - Eur J Cancer PY - 2008 VL - 44 SP - 2112 EP - 2117 UR - https://doi.org/10.1016/j.ejca.2008.07.008 ER - TY - JOUR LB - 27. AU - Baum, HV AU - Franz, U AU - Geiss, HK TI - Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients J2 - Infection PY - 2000 VL - 28 SP - 278 EP - 281 UR - https://doi.org/10.1007/s150100070019 ER - TY - JOUR LB - 28. AU - Razonable, RR AU - Litzow, MR AU - Khaliq, Y AU - Piper, KE AU - Rouse, MS AU - Patel, R TI - Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis J2 - Clin Infect Dis PY - 2002 VL - 34 SP - 1469 EP - 1474 UR - https://doi.org/10.1086/340352 ER - TY - JOUR LB - 29. AU - Kyle, RA AU - Rajkumar, SV TI - Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma J2 - Leukemia PY - 2009 VL - 23 SP - 3 EP - 9 UR - https://doi.org/10.1038/leu.2008.291 ER - TY - JOUR LB - 30. AU - Rajkumar, SV AU - Dimopoulos, MA AU - Palumbo, A AU - Blade, J AU - Merlini, G AU - Mateos, MV TI - International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma J2 - Lancet Oncol PY - 2014 VL - 15 SP - e538 EP - e548 UR - https://doi.org/10.1016/S1470-2045(14)70442-5 ER - TY - JOUR LB - 31. AU - EuroQol Group TI - EuroQol-a new facility for the measurement of health-related quality of life J2 - Health Policy PY - 1990 VL - 16 SP - 199 EP - 208 UR - https://doi.org/10.1016/0168-8510(90)90421-9 ER - TY - JOUR LB - 32. AU - Rowen, D AU - Brazier, J AU - Young, T AU - Gaugris, S AU - Craig, BM AU - King, MT AU - Velikova, G TI - Deriving a preference-based measure for cancer using the EORTC QLQ-C30 J2 - Value Health PY - 2011 VL - 14 SP - 721 EP - 731 UR - https://doi.org/10.1016/j.jval.2011.01.004 ER - TY - JOUR LB - 33. AU - Zigmond, AS AU - Snaith, RP TI - The hospital anxiety and depression scale J2 - Acta Psychiatr Scand PY - 1983 VL - 67 SP - 361 EP - 370 UR - https://doi.org/10.1111/j.1600-0447.1983.tb09716.x ER - TY - JOUR LB - 34. AU - Kaplan, MM P TI - Non parametric estimation from incomplete observations J2 - J Am Stat Assoc PY - 1958 VL - 53 SP - 457 EP - 481 UR - https://doi.org/10.1080/01621459.1958.10501452 ER - TY - JOUR LB - 35. AU - Peto, R AU - Pike, MC AU - Armitage, P AU - Breslow, NE AU - Cox, DR AU - Howard, SV TI - Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples J2 - Br J Cancer PY - 1977 VL - 35 SP - 1 EP - 39 UR - https://doi.org/10.1038/bjc.1977.1 ER - TY - JOUR LB - 36. AU - Cox, R TI - Regression models and life-tables J2 - J R Stat Soc Series B Stat Methodol PY - 1972 VL - 34 SP - 187 EP - 220 ER - TY - JOUR LB - 37. AU - Royston, P AU - Parmar, MK TI - Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome J2 - BMC Med Res Methodol PY - 2013 VL - 13 SP - 152 UR - https://doi.org/10.1186/1471-2288-13-152 ER - TY - JOUR LB - 38. AU - Félix, J AU - Aragão, F AU - Almeida, JM AU - Calado, FJ AU - Ferreira, D AU - Parreira, AB TI - Time-dependent endpoints as predictors of overall survival in multiple myeloma J2 - BMC Cancer PY - 2013 VL - 13 SP - 122 UR - https://doi.org/10.1186/1471-2407-13-122 ER - TY - GEN LB - 39. AU - National Institute of Health and Care Excellence (NICE) TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE PY - 2013 ER - TY - BOOK LB - 40. AU - Glick, HA AU - Doshi, JA AU - Sonnad, SS AU - Polsky, D TI - Economic Evaluation in Clinical Trials ET - 2nd edn. CY - Oxford PB - Oxford University Press PY - 2014 UR - https://doi.org/10.1093/med/9780199685028.001.0001 ER - TY - JOUR LB - 41. AU - Dolan, P TI - Modeling valuations for EuroQol health states J2 - Med Care PY - 1997 VL - 35 SP - 1095 EP - 1108 UR - https://doi.org/10.1097/00005650-199711000-00002 ER - TY - ELEC LB - 42. AU - Joint Formulary Committee TI - British National Formulary UR - www.medicinescomplete.com/mc/bnf/current/ M1 - 30 November 2017 ER - TY - BOOK LB - 43. AU - Curtis, LB TI - Unit Costs of Health and Social Care 2015 CY - Canterbury PB - PSSRU, University of Kent PY - 2015 ER - TY - GEN LB - 44. AU - Department of Health and Social Care (DHSC) TI - NHS Reference Costs 2014 to 2015 CY - London PB - DHSC PY - 2015 UR - www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 Y2 - 30 November 2017 ER - TY - BOOK LB - 45. AU - Curtis, LB TI - Unit Costs of Health and Social Care 2016 CY - Canterbury PB - PSSRU, University of Kent PY - 2016 ER - TY - GEN LB - 46. AU - Department of Health and Social Care (DHSC) TI - NHS Reference Costs 2015 to 2016 CY - London PB - DHSC PY - 2016 UR - www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 Y2 - 30 November 2017 ER - TY - JOUR LB - 47. AU - Manca, A AU - Hawkins, N AU - Sculpher, MJ TI - Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility J2 - Health Econ PY - 2005 VL - 14 SP - 487 EP - 496 UR - https://doi.org/10.1002/hec.944 ER - TY - JOUR LB - 48. AU - Hunter, RM AU - Baio, G AU - Butt, T AU - Morris, S AU - Round, J AU - Freemantle, N TI - An educational review of the statistical issues in analysing utility data for cost-utility analysis J2 - PharmacoEconomics PY - 2015 VL - 33 SP - 355 EP - 366 UR - https://doi.org/10.1007/s40273-014-0247-6 ER - TY - JOUR LB - 49. AU - Faria, R AU - Gomes, M AU - Epstein, D AU - White, IR TI - A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials J2 - PharmacoEconomics PY - 2014 VL - 32 SP - 1157 EP - 1170 UR - https://doi.org/10.1007/s40273-014-0193-3 ER - TY - JOUR LB - 50. AU - Ramsey, SD AU - Willke, RJ AU - Glick, H AU - Reed, SD AU - Augustovski, F AU - Jonsson, B TI - Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report J2 - Value Health PY - 2015 VL - 18 SP - 161 EP - 172 UR - https://doi.org/10.1016/j.jval.2015.02.001 ER - TY - JOUR LB - 51. AU - White, IR AU - Thompson, SG TI - Adjusting for partially missing baseline measurements in randomized trials J2 - Stat Med PY - 2005 VL - 24 SP - 993 EP - 1007 UR - https://doi.org/10.1002/sim.1981 ER - TY - BOOK LB - 52. AU - Drummond, MF AU - Sculpher, MJ AU - Claxton, K AU - Stoddart, GL AU - Torrance, GW TI - Methods for the Economic Evaluation of Health Care Programmes ET - 4th edn. CY - Oxford PB - Oxford University Press PY - 2015 ER - TY - JOUR LB - 53. AU - O’Brien, BJ AU - Briggs, AH TI - Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods J2 - Stat Methods Med Res PY - 2002 VL - 11 SP - 455 EP - 468 UR - https://doi.org/10.1191/0962280202sm304ra ER - TY - JOUR LB - 54. AU - Briggs, AH AU - O’Brien, BJ AU - Blackhouse, G TI - Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies J2 - Annu Rev Public Health PY - 2002 VL - 23 SP - 377 EP - 401 UR - https://doi.org/10.1146/annurev.publhealth.23.100901.140534 ER - TY - BOOK LB - 55. AU - Edlin, R AU - McCabe, C AU - Hulme, C AU - Hall, P AU - Wright, J TI - Cost Effectiveness Modelling for Health Technology Assessment PB - Cham: Adis Springer Nature PY - 2015 UR - https://doi.org/10.1007/978-3-319-15744-3 ER - TY - JOUR LB - 56. AU - Phillips, CV TI - The economics of ‘more research is needed’ J2 - Int J Epidemiol PY - 2001 VL - 30 SP - 771 EP - 776 UR - https://doi.org/10.1093/ije/30.4.771 ER - TY - ELEC LB - 57. AU - National Cancer Registration and Analysis Service TI - Routes to Diagnosis 2006–2010 Workbook UR - www.ncin.org.uk/publications/routes_to_diagnosis ER - TY - JOUR LB - 58. AU - Gafter-Gvili, A AU - Fraser, A AU - Paul, M AU - Leibovici, L TI - Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients J2 - Ann Intern Med PY - 2005 VL - 142 SP - 979 EP - 995 UR - https://doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00008 ER -